Jonathan Braun's laboratory will use a cross-sectional study to correlate genotoxicity markers to mucosal healing and disease activity in IBD patients, while Prometheus will assess other markers associated with the diagnosis and prognosis of IBD.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.